With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle ...

After moving from Sierra Leone to London, guest columnist Richard Bayliss received a proper diagnosis and care plan for his ...

Richard Bayliss is 44 years old and has sickle cell disease with hemoglobin SS disease. He’s in the final year of a master’s ...

Columnist Mary Shaniqua explains how to be an ally to the sickle cell community, and why that kind of support is essential ...